Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: RYBP

Gene summary for RYBP

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

RYBP

Gene ID

23429

Gene nameRING1 and YY1 binding protein
Gene AliasAAP1
Cytomap3p13
Gene Typeprotein-coding
GO ID

GO:0000122

UniProtAcc

Q8N488


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
23429RYBPHTA11_3410_2000001011HumanColorectumAD4.85e-12-4.61e-010.0155
23429RYBPHTA11_3361_2000001011HumanColorectumAD9.71e-05-4.91e-01-0.1207
23429RYBPHTA11_866_3004761011HumanColorectumAD1.54e-07-4.30e-010.096
23429RYBPHTA11_7696_3000711011HumanColorectumAD6.69e-06-3.43e-010.0674
23429RYBPHTA11_99999974143_84620HumanColorectumMSS7.74e-07-4.11e-010.3005
23429RYBPA001-C-207HumanColorectumFAP6.57e-03-2.65e-010.1278
23429RYBPA015-C-203HumanColorectumFAP2.75e-19-3.97e-01-0.1294
23429RYBPA015-C-204HumanColorectumFAP9.88e-06-2.69e-01-0.0228
23429RYBPA014-C-040HumanColorectumFAP6.75e-05-4.78e-01-0.1184
23429RYBPA002-C-201HumanColorectumFAP1.03e-11-3.50e-010.0324
23429RYBPA001-C-119HumanColorectumFAP1.36e-13-5.53e-01-0.1557
23429RYBPA001-C-108HumanColorectumFAP3.32e-13-4.76e-01-0.0272
23429RYBPA002-C-205HumanColorectumFAP2.69e-23-5.36e-01-0.1236
23429RYBPA001-C-104HumanColorectumFAP1.16e-04-3.47e-010.0184
23429RYBPA015-C-005HumanColorectumFAP9.67e-10-4.17e-01-0.0336
23429RYBPA015-C-006HumanColorectumFAP5.18e-16-5.22e-01-0.0994
23429RYBPA015-C-106HumanColorectumFAP2.85e-09-3.65e-01-0.0511
23429RYBPA002-C-114HumanColorectumFAP8.03e-17-4.51e-01-0.1561
23429RYBPA015-C-104HumanColorectumFAP1.68e-24-5.51e-01-0.1899
23429RYBPA001-C-014HumanColorectumFAP4.70e-10-3.80e-010.0135
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
LungThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AAH: Atypical adenomatous hyperplasia
AIS: Adenocarcinoma in situ
IAC: Invasive lung adenocarcinoma
MIA: Minimally invasive adenocarcinoma
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:19033622ColorectumMSSregulation of cellular protein catabolic process99/3467255/187231.90e-145.37e-1299
GO:00104982ColorectumMSSproteasomal protein catabolic process157/3467490/187232.39e-135.25e-11157
GO:00313302ColorectumMSSnegative regulation of cellular catabolic process96/3467262/187232.67e-124.63e-1096
GO:00098952ColorectumMSSnegative regulation of catabolic process110/3467320/187237.88e-121.20e-09110
GO:19030502ColorectumMSSregulation of proteolysis involved in cellular protein catabolic process82/3467221/187234.97e-115.64e-0982
GO:00431612ColorectumMSSproteasome-mediated ubiquitin-dependent protein catabolic process127/3467412/187237.70e-106.32e-08127
GO:20000582ColorectumMSSregulation of ubiquitin-dependent protein catabolic process61/3467164/187231.28e-087.61e-0761
GO:00611362ColorectumMSSregulation of proteasomal protein catabolic process67/3467187/187231.45e-088.47e-0767
GO:19033632ColorectumMSSnegative regulation of cellular protein catabolic process34/346775/187238.96e-084.44e-0634
GO:00421772ColorectumMSSnegative regulation of protein catabolic process47/3467121/187231.28e-076.01e-0647
GO:00324342ColorectumMSSregulation of proteasomal ubiquitin-dependent protein catabolic process49/3467134/187236.02e-072.26e-0549
GO:20000592ColorectumMSSnegative regulation of ubiquitin-dependent protein catabolic process22/346748/187231.33e-053.07e-0422
GO:00458612ColorectumMSSnegative regulation of proteolysis97/3467351/187231.57e-053.54e-0497
GO:19030512ColorectumMSSnegative regulation of proteolysis involved in cellular protein catabolic process26/346764/187233.19e-056.30e-0426
GO:00324352ColorectumMSSnegative regulation of proteasomal ubiquitin-dependent protein catabolic process17/346735/187235.07e-059.12e-0417
GO:19017992ColorectumMSSnegative regulation of proteasomal protein catabolic process19/346749/187237.20e-047.70e-0319
GO:0016570ColorectumMSShistone modification113/3467463/187238.37e-048.68e-03113
GO:00335221ColorectumMSShistone H2A ubiquitination12/346726/187231.16e-031.12e-0212
GO:00065131ColorectumMSSprotein monoubiquitination21/346767/187237.90e-034.84e-0221
GO:0016574ColorectumMSShistone ubiquitination16/346747/187238.22e-034.99e-0216
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
RYBPSNVMissense_Mutationnovelc.470G>Ap.Val158Ilep.V158IQ8N488protein_codingdeleterious(0)probably_damaging(0.991)TCGA-A8-A08R-01Breastbreast invasive carcinomaFemale<65I/IIUnknownUnknownSD
RYBPSNVMissense_Mutationnovelc.247G>Cp.Glu83Aspp.E83DQ8N488protein_codingtolerated(0.57)benign(0)TCGA-AR-A2LH-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapyadriamycinPD
RYBPinsertionFrame_Shift_Insnovelc.459_460insTTCTATTTCATTCTCTTCAp.Asn155SerfsTer16p.N155Sfs*16Q8N488protein_codingTCGA-AO-A0J9-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapycyclophosphamidePD
RYBPinsertionNonsense_Mutationnovelc.458_459insACATAAAGATAGCTTGAGTAAACTp.Gly154delinsAspIleLysIleAlaTerValAsnCysp.G154delinsDIKIA*VNCQ8N488protein_codingTCGA-AO-A0J9-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapycyclophosphamidePD
RYBPSNVMissense_Mutationnovelc.515T>Cp.Ser173Prop.S173PQ8N488protein_codingdeleterious(0.05)benign(0.127)TCGA-AA-A010-01Colorectumcolon adenocarcinomaFemale<65I/IIChemotherapyfolinicCR
RYBPSNVMissense_Mutationc.407C>Tp.Arg137Trpp.R137WQ8N488protein_codingdeleterious(0.01)probably_damaging(0.916)TCGA-AZ-4313-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
RYBPSNVMissense_Mutationnovelc.570N>Tp.Ser191Leup.S191LQ8N488protein_codingdeleterious(0)probably_damaging(0.99)TCGA-AZ-4315-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
RYBPSNVMissense_Mutationnovelc.282N>Cp.Lys95Thrp.K95TQ8N488protein_codingdeleterious(0)probably_damaging(0.937)TCGA-CA-6717-01Colorectumcolon adenocarcinomaMale<65I/IIChemotherapyoxaliplatinCR
RYBPSNVMissense_Mutationnovelc.132N>Ap.Pro45Hisp.P45HQ8N488protein_codingdeleterious(0)probably_damaging(0.991)TCGA-A5-A1OF-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
RYBPSNVMissense_Mutationnovelc.144N>Tp.Ser49Phep.S49FQ8N488protein_codingdeleterious(0)probably_damaging(0.989)TCGA-AX-A05Z-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapyadriamycinSD
Page: 1 2 3 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1